These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 28527325)

  • 21. [PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease].
    Thiery J; Burkhardt R
    Herz; 2016 Jun; 41(4):281-9. PubMed ID: 27215417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council.
    Hegele RA; Gidding SS; Ginsberg HN; McPherson R; Raal FJ; Rader DJ; Robinson JG; Welty FK
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2269-80. PubMed ID: 26376908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial Hypercholesterolemia.
    Robinson JG
    Prog Cardiovasc Dis; 2016; 59(2):165-171. PubMed ID: 27498088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid-lowering agents.
    Ewang-Emukowhate M; Wierzbicki AS
    J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):401-11. PubMed ID: 23811423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H; Burns TL; Hilleman DE
    Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery Approaches for Novel Dyslipidemia Drugs.
    Maqbool F; Safavi M; Bahadar H; Rahimifard M; Niaz K; Abdollahi M
    Curr Drug Discov Technol; 2015; 12(2):90-116. PubMed ID: 26135857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management.
    Johnston TP; Korolenko TA; Pirro M; Sahebkar A
    Pharmacol Res; 2017 Jun; 120():219-225. PubMed ID: 28408313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L; Peng H; Xu D; Zhao S
    Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inclisiran for the treatment of dyslipidemia.
    Nishikido T; Ray KK
    Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Homozygous familial hypercholesterolaemia: update on management.
    France M
    Paediatr Int Child Health; 2016 Nov; 36(4):243-247. PubMed ID: 27967828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proprotein Convertase Subtilism/Kexin 9 (PCSK9) Inhibitors: Adding to the Armamentarium of the Primary Care Physician.
    Coy K; Stys A; Stys T; DeVries J
    S D Med; 2021 Oct; 74(10):454-456. PubMed ID: 34995425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-density lipoprotein cholesterol lowering therapies: what is on the horizon?
    Gadi R; Figueredo VM
    J Cardiovasc Med (Hagerstown); 2015 Jan; 16(1):1-10. PubMed ID: 25379719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigational therapies for the treatment of atherosclerosis.
    Tomkin GH; Owens D
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1411-21. PubMed ID: 24857672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
    Okere AN; Serra C
    Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PCSK9 inhibitors--past, present and future.
    Reiner Ž
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1517-21. PubMed ID: 26329686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LDL-Cholesterol: Standards of Treatment 2016: A German Perspective.
    März W; Scharnagl H; Gouni-Berthold I; Silbernagel G; Dressel A; Grammer TB; Landmesser U; Dieplinger H; Windler E; Laufs U
    Am J Cardiovasc Drugs; 2016 Oct; 16(5):323-36. PubMed ID: 27430233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apolipoprotein B antisense inhibition--update on mipomersen.
    Gebhard C; Huard G; Kritikou EA; Tardif JC
    Curr Pharm Des; 2013; 19(17):3132-42. PubMed ID: 23317401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular risk reduction: the future of cholesterol lowering drugs.
    Bou Malham S; Goldberg AC
    Curr Opin Pharmacol; 2016 Apr; 27():62-9. PubMed ID: 26939026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biologics for the treatment of dyslipidemias: a look beyond conventional therapy.
    Yoon CH; Watson K
    Ann Pharmacother; 2014 Feb; 48(2):238-49. PubMed ID: 24259646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.